Glycologix Revenue and Competitors
Estimated Revenue & Valuation
- Glycologix's estimated annual revenue is currently $1.7M per year.
- Glycologix's estimated revenue per employee is $155,000
Employee Data
- Glycologix has 11 Employees.
- Glycologix grew their employee count by 10% last year.
Glycologix's People
Name | Title | Email/Phone |
---|
Glycologix Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Glycologix?
Glycologix LLC is an emerging biotechnology company targeting the repair and rejuvenation of soft tissues. Joint repair, spinal disk disease, and disturbances in the skin and bladder can all be addressed by replenishment of naturally occurring proteoglycans. Target indications include interstitial cystitis, rhinosinusitis, osteoarthritis, rosacea, and cosmetics. A platform discovery engine enables the preparation of synthetic structural mimics of naturally occurring proteoglycans. These novel materials are branched, sulfated, high molecular weight and easily microfiltered. This proprietary chemistry know how enables the casual optimization of target polymer properties to rapidly address many therapeutics areas. Glycologix is supported by grants from the National Institutes of Health as well as individual investors.
keywords:N/AN/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.7M | 11 | 0% | N/A |
#2 | $0.9M | 11 | 22% | N/A |
#3 | $1.7M | 11 | -8% | N/A |
#4 | $2.3M | 12 | N/A | N/A |
#5 | $1M | 12 | -20% | N/A |